Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125090253 | 12509025 | 3 | F | 20151130 | 20160824 | 20160629 | 20160831 | EXP | GB-ACTAVISPR-2016-12100 | GB-FRI-1000085602 | FOREST | 50.57 | YR | F | Y | 0.00000 | 20160831 | OT | DK | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125090253 | 12509025 | 1 | PS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 10 MG ONCE DAILY | 20822 | 10 | MG | QD | |||||||
125090253 | 12509025 | 2 | SS | CITALOPRAM | CITALOPRAM HYDROBROMIDE | 1 | Oral | 20 MG ONCE DAILY | 20822 | 20 | MG | QD | |||||||
125090253 | 12509025 | 3 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Unknown | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125090253 | 12509025 | 1 | Anxiety |
125090253 | 12509025 | 3 | Abdominal pain |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125090253 | 12509025 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125090253 | 12509025 | Abdominal pain upper | |
125090253 | 12509025 | Cerebral haemorrhage | |
125090253 | 12509025 | Cerebrovascular accident | |
125090253 | 12509025 | Head injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125090253 | 12509025 | 1 | 2008 | 0 |